Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: Effects of HER2 abundance

Translational Oncology

Volumn 4, Issue 5, 2011, Pages 293-300

  Emde, Anna ^a   Mahlknecht, Georg ^a   Maslak, Kerstin ^b   Ribba, Benjamin ^c   Sela, Michael ^a   Possinger, Kurt ^b   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; PROTEIN EXPRESSION;

EID: 80053341141     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11127     Document Type: Article

References (38)

1. Clark GM and McGuire WL (1988). Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15, 20-25.
2. Allred DC, Brown P, and Medina D (2004). The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Res 6, 240-245.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. (1989). Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244, 707-712.
4. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, and Osborne CK (2004). Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10, 331S-336S.
5. Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med 339, 1609-1618.
6. Osborne CK and Schiff R (2011). Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62, 233-247.
7. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, et al. (2005). Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104, 257-263.
8. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, et al. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101, 9393-9398.
9. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, and Lee AV (2008). Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26, 4078-4085.
10. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, and Schiff R (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68, 826-833.
11. Dowsett M (2001). Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8, 191-195.
12. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, and Schiff R (2006). Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor- positive, HER-2/neu-positive breast cancer. Cancer Res 66, 8266-8273.
13. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, and Elledge RM (2004). HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10, 5670-5676.
14. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, et al. (2006). Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24, 3019-3025.
15. Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137.
16. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, and Stoica A (2003). Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17, 818-830.
17. Wong A, Lamothe B, Lee A, Schlessinger J, and Lax I (2002). FRS2α attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA 99, 6684-6689.
18. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, and Spector NL (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255-6263.
19. Chu I, Blackwell K, Chen S, and Slingerland J (2005). The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65, 18-25.
20. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, et al. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27, 5538-5546.
21. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, et al. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor- positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27, 5529-5537.
22. Dauvois S, White R, and Parker MG (1993). The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106(Pt 4), 1377-1388.
23. Dowsett M, Nicholson RI, and Pietras RJ (2005). Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93(suppl 1), S11-S18.
24. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17, 2639-2648.
25. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, and Sela M (1997). A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14, 2099-2109.
26. Sutherland RL, Reddel RR, and Green MD (1983). Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur J Cancer Clin Oncol 19, 307-318.
27. Sutherland RL, Green MD, Hall RE, Reddel RR, and Taylor IW (1983). Tamoxifen induces accumulation of MCF7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19, 615-621.
28. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, and Nicholson RI (2003). The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144, 5105-5117.
29. Emde A, Pradeep CR, Ferraro DA, Ben-Chetrit N, Sela M, Ribba B, Kam Z, and Yarden Y (2011). Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 30, 1631-1642.
30. Bender LM and Nahta R (2008). Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 13, 3906-3912.
31. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, and Schiff R (2008). Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68, 7493-7501.
32. Chen FL, Xia W, and Spector NL (2008). Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14, 6730-6734.
33. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, et al. (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28, 4594-4600.
34. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, et al. (2006). A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103, 7795-7800.
35. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, et al. (2010). Growth factor stimulation induces a distinct ER(α) cistrome underlying breast cancer endocrine resistance. Genes Dev 24, 2219-2227.
36. Yang Z, Barnes CJ, and Kumar R (2004). Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin Cancer Res 10, 3621-3628.
37. Amit I, Wides R, and Yarden Y (2007). Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 3, 151.
38. Stelling J, Sauer U, Szallasi Z, Doyle FJ III, and Doyle J (2004). Robustness of cellular functions. Cell 118, 675-685.